ArriVent
AVBPArriVent BioPharma, Inc. Common Stock Price (AVBP)
Stock Price
Market Cap
Fetching Data...
Enterprise Value
Fetching Data...
Volume
Fetching Data...
Shares Outstanding
31,956,657
(4.5892)%Revenue and Profitability
| Year | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | - |
| Net Income | -51,606,000 | -36,906,000 | -69,333,000 | - |
| FCF USD | -12,587,000 | -43,631,000 | -55,842,000 | -70,212,000 |
| OCF USD | -12,587,000 | -43,631,000 | -55,842,000 | -70,212,000 |
Financial Health - DEBT
| Year | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|
| YTPD | 0.00 | 0.00 | 0.00 | 0.00 |
| D/E | 0.00 | 0.00 | 0.00 | 0.00 |
| CA/CL | 23.63 | 21.84 | 13.76 | 13.14 |
| TA/TL | 23.67 | 21.84 | 13.82 | 15.90 |
| Total Debt | 0 | 139,000 | 317,000 | 176,000 |
Management Performance
| Year | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|
| ROIC | -16.36% | 0.00% | -49.20% | - |
| ROE | -125.19% | -21.15% | -45.83% | - |
| ROA | 0.00% | -20.19% | -42.51% | -29.27% |
| NM % | - | - | - | - |
| FCF / R% | 0.00% | 0.00% | 0.00% | 0.00% |
| FCF / NI% | 24.39% | 118.22% | 80.54% | 87.23% |
| Operating Margin (OM) | - | - | - | - |
Per Share
| Year | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|
| EPS | -1.54 | -1.10 | -2.17 | 0.00 |
| SPS | 0.00 | 0.00 | 0.00 | 0.00 |
| OCPS | -0.38 | -1.30 | -1.75 | 0.00 |
| FCPS | -0.38 | -1.30 | -1.75 | 0.00 |
| BVPS | 1.23 | 5.21 | 4.73 | 0.00 |
Per Share - CAGR
| Year | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|
| CAGR-EPS | -1.54 | -1.10 | -2.17 | 0.00 |
| CAGR-SPS | 0.00 | 0.00 | 0.00 | 0.00 |
| CAGR-OCPS | -0.38 | -1.30 | -1.75 | 0.00 |
| CAGR-FCPS | -0.38 | -1.30 | -1.75 | 0.00 |
| CAGR-BVPS | 1.23 | 5.21 | 4.73 | 0.00 |